Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/133837
Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)
Matèries (anglès)
Citació
Col·leccions
Citació
SICRAS MAINAR, Antoni, REJAS, Javier, PÉREZ-PARAMO, Maria, SÁNCHEZ-ÁLVAREZ, Luis, NAVARRO-ARTIEDA, Ruth, DARBÀ, Josep. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin. _Expert Review of Pharmacoeconomics & Outcomes Research_. 2019. Vol. 19, núm. 1, pàgs. 45-57. [consulta: 28 de gener de 2026]. ISSN: 1473-7167. [Disponible a: https://hdl.handle.net/2445/133837]